供者选择与异基因造血干细胞移植后白血病复发中的HLA缺失
该研究分析全球27中心533例allo-HCT后血液肿瘤复发,用新建NGS流程检测HLA缺失。HLA缺失占复发15.6%,随供者类型显著变化;HLA错配位于同一单倍型时缺失率27.6%,位于不同单倍型时5.4%。HLA缺失使原供者淋巴细胞输注失效,二次allo-HCT换供者可获生存优势,提示复发时应常规评估HLA缺失以指导供者选择与挽救治疗。
要点
- allo-HCT后复发中HLA缺失占15.6%,单倍体供者最高28.7%。
- HLA错配位于同一单倍型时缺失风险27.6%,不同单倍型仅5.4%。
- HLA缺失使原供者淋巴细胞输注失效,换供者二次移植有生存优势。
核心结论
- HLA缺失风险随患者与供者HLA错配的数量和单倍型位置显著变化。
- 新建单倍型推断工具可可靠预测HLA缺失风险,支持知情供者选择。
- 复发时HLA缺失影响免疫挽救治疗成功,应常规评估。
研究设计与样本
- 分析全球27中心533例allo-HCT后血液肿瘤复发,涵盖不同供者类型。
- 采用新开发的新一代测序流程评估错配HLA的基因组缺失。
主要发现
- HLA缺失发生于15.6%的复发,供者类型间差异显著:单倍体家族供者28.7%、无关成人供者7.2%、脐血2.7%(P < .0001)。
- HLA错配位于同一单倍型时缺失发生率27.6%,位于不同单倍型时5.4%(P < .0001)。
- HLA缺失消除原供者淋巴细胞输注的疗效,换用不同供者二次allo-HCT有显著生存优势。
临床怎么用
- 供者选择时应考虑HLA错配的数量与单倍型位置,可用单倍型推断工具预测HLA缺失风险。
- 复发时应常规评估HLA缺失,因其影响免疫挽救治疗(如供者淋巴细胞输注)的成功。
- 对HLA缺失复发者,可考虑换用不同供者行二次allo-HCT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: For patients with hematologic malignancies, relapse is the leading cause of death after allogeneic hematopoietic cell transplantation (allo-HCT). Frequently, relapses are explained by immune evasion through alterations of human leukocyte antigens (HLAs), but determinants and clinical consequences remain poorly defined. METHODS: We analyzed 533 relapses of hematologic cancers after allo-HCT from different donor types, conducted at 27 centers worldwide. Genomic loss of mismatched HLA (HLA loss) was assessed using a newly developed next-generation sequencing pipeline. Clinical and immunogenetic factors associated with HLA loss were evaluated. Using HLA data from approximately 5 million individuals, a web-based tool to infer HLA incompatibility phasing was developed. RESULTS: HLA loss occurred in 15.6% of relapses, with significant variation according to donor type (28.7% haploidentical family, 7.2% unrelated adult, 2.7% cord blood, P < .0001). The distribution of HLA mismatches across the patient's haplotypes, predicted through the phasing tool, was strongly associated with HLA loss, with an incidence of 27.6% when HLA mismatches were in the same haplotype, compared with 5.4% if present on different haplotypes (P < .0001). HLA loss affected postrelapse outcomes, abrogating the efficacy of original donor lymphocyte infusions, with significant survival advantage by second allo-HCT from a different donor. CONCLUSION: The likelihood of HLA loss varies significantly according to the number and positioning of HLA mismatches between patient and donor. A newly developed phasing tool enables reliable prediction of its risk, supporting informed donor selection. Routine assessment of HLA loss at relapse is warranted, as it critically affects the success of immunologic salvage therapies.
引用
- Fleischhauer K, Toffalori C, Cugnata F, et al. Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation. J Clin Oncol. 2026. PMID: 42348822. doi:10.1200/JCO-26-00113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。